

Jean-Sebastien Frenel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4920242/publications.pdf>

Version: 2024-02-01

65
papers

2,469
citations

361413

20
h-index

206112

48
g-index

79
all docs

79
docs citations

79
times ranked

4976
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1â€“Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 4035-4041.	1.6	375
2	Tumor clone dynamics in lethal prostate cancer. <i>Science Translational Medicine</i> , 2014, 6, 254ra125.	12.4	298
3	bc-GenExMiner 3.0: new mining module computes breast cancer gene expression correlation analyses. Database: the <i>Journal of Biological Databases and Curation</i> , 2013, 2013, bas060-bas060.	3.0	211
4	Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration. <i>Clinical Cancer Research</i> , 2015, 21, 4586-4596.	7.0	171
5	Global cancer control: responding to the growing burden, rising costs and inequalities in access. <i>ESMO Open</i> , 2018, 3, e000285.	4.5	169
6	Could any pT1a,bNOMO hormone-responsive, invasive breast carcinomas be safely treated without endocrine therapy?. <i>Journal of Clinical Oncology</i> , 2015, 33, 550-550.	1.6	118
7	Phase II Study of Radiotherapy and Temozolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without <i>MGMT</i> Promoter Hypermethylation (EORTC 26082). <i>Clinical Cancer Research</i> , 2016, 22, 4797-4806.	7.0	105
8	Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 307-318.	2.5	101
9	Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. <i>Annals of Oncology</i> , 2018, 29, 2334-2340.	1.2	97
10	Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas. <i>British Journal of Cancer</i> , 2008, 98, 1993-1998.	6.4	64
11	Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094093.	3.2	55
12	Pembrolizumab in patients with advanced cervical squamous cell cancer: Preliminary results from the phase Ib KEYNOTE-028 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5515-5515.	1.6	53
13	Oxaliplatinâ€based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: A pilot study of 31 patients. <i>Journal of Surgical Oncology</i> , 2011, 103, 10-16.	1.7	46
14	Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series. <i>Annals of Oncology</i> , 2013, 24, 916-924.	1.2	43
15	Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 335-346.	3.2	39
16	Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas. <i>Neurology</i> , 2015, 85, 1325-1331.	1.1	34
17	Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience. <i>Journal of Neuro-Oncology</i> , 2013, 114, 85-91.	2.9	28
18	5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study. <i>European Journal of Cancer</i> , 2018, 95, 30-37.	2.8	26

#	ARTICLE	IF	CITATIONS
19	Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 559-566.	2.5	26
20	Recent trends in breast cancer incidence rates in the Loire-Atlantique, France: A decline since 2003. <i>Cancer Epidemiology</i> , 2010, 34, 238-243.	1.9	24
21	Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas. <i>International Journal of Oncology</i> , 2012, 40, 2058-62.	3.3	23
22	Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 2509.	3.7	22
23	miR-370-3p Is a Therapeutic Tool in Anti-glioblastoma Therapy but Is Not an Intratumoral or Cell-free Circulating Biomarker. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 13, 642-650.	5.1	21
24	Olaparib for the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 751-759.	4.1	20
25	Prevalence of Proton Pump Inhibitor Use Among Patients With Cancer. <i>JAMA Network Open</i> , 2021, 4, e2113739.	5.9	19
26	Eribulin mesylate for the treatment of late-stage breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2883-2890.	1.8	17
27	Prognostic factors for patients treated for a recurrent FIGO stage III ovarian cancer: A retrospective study of 108 cases. <i>European Journal of Surgical Oncology</i> , 2011, 37, 971-977.	1.0	16
28	Phase II part of EORTC study 26101: The sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2019-2019.	1.6	14
29	Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592098765.	3.2	13
30	Radiation therapy and concurrent plus adjuvant temsirolimus (CCI-779) versus chemoradiation with temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2003-2003.	1.6	13
31	NY-ESO-1-Specific Circulating CD4+ T Cells in Ovarian Cancer Patients Are Prevalently TH1 Type Cells Undetectable in the CD25+FOXP3+Treg Compartment. <i>PLoS ONE</i> , 2011, 6, e22845.	2.5	12
32	An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1) Tj ETQq0 0 0 rgBT /Overlock 1 tumors. <i>Anti-Cancer Drugs</i> , 2016, 27, 342-348.	1.4	12
33	Emotional distress and subjective impact of the disease in young women with breast cancer and their spouses. <i>Future Oncology</i> , 2017, 13, 2667-2680.	2.4	12
34	Vinflunine for the treatment of breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1817-1823.	1.8	10
35	Emerging PARP inhibitors for treating breast cancer. <i>Expert Opinion on Emerging Drugs</i> , 2018, 23, 211-221.	2.4	10
36	Benefits versus risk profile of buparlisib for the treatment of breast cancer. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 553-562.	2.4	10

#	ARTICLE	IF	CITATIONS
37	Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux â€“M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).. Journal of Clinical Oncology, 2018, 36, 2023-2023.	1.6	10
38	Bevacizumab Efficacy Is Influenced by Primary Tumor Resection in First-Line Treatment of Metastatic Colorectal Cancer in a Retrospective Multicenter Study. Clinical Colorectal Cancer, 2016, 15, e165-e174.	2.3	9
39	Management of Fournier's gangrene non-healing wounds by autologous skin micrograft biotechnology: a new technique. Journal of Wound Care, 2017, 26, 314-317.	1.2	9
40	The self-reported perceptions of the repercussions of the disease and its treatments on daily life for young women with breast cancer and their partners. Journal of Psychosocial Oncology, 2019, 37, 50-68.	1.2	9
41	Cell-free circulating epimarks in cancer monitoring. Epigenomics, 2020, 12, 145-155.	2.1	8
42	Efficacy of buparlisib in treating breast cancer. Expert Opinion on Pharmacotherapy, 2017, 18, 2007-2016.	1.8	8
43	An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer. Drugs, 2018, 78, 1353-1362.	10.9	6
44	Adjustment of young women with breast cancer after chemotherapy: A mediation model of emotional competence via emotional distress. Psycho-Oncology, 2022, 31, 848-855.	2.3	6
45	Long-Term Use of Proton Pump Inhibitors in Cancer Patients: An Opinion Paper. Cancers, 2022, 14, 1156.	3.7	6
46	Pharmacokinetic drug evaluation of abemaciclib for advanced breast cancer. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 85-91.	3.3	5
47	Real-world evidence of the management and prognosis of young women (â©½40â€“years) with de novo metastatic breast cancer. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592110703.	3.2	4
48	Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial. Cancers, 2022, 14, 1189.	3.7	3
49	Clinical evidence for the role of eribulin mesylate in the treatment of breast cancer. Clinical Investigation, 2012, 2, 207-213.	0.0	2
50	Medical oncologists must get more involved in systemic treatment. Annals of Oncology, 2019, 30, 6-8.	1.2	2
51	Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210770.	3.2	2
52	Optimizing the Retrieval of the Vital Status of Cancer Patients for Health Data Warehouses by Using Open Government Data in France. International Journal of Environmental Research and Public Health, 2022, 19, 4272.	2.6	2
53	Survival Outcomes after Hyperthermic Intraperitoneal Chemotherapy for a First Ovarian Cancer Relapse: A Systematic Evidence-Based Review. Cancers, 2022, 14, 172.	3.7	2
54	Aquacel Surgical Dressing after Thigh Lift. Plastic and Reconstructive Surgery - Global Open, 2016, 4, e863.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Patient-centered simulations to assess the usefulness of the 70-gene signature for adjuvant chemotherapy administration in early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 537-542.	2.5	1
56	Abstract 1189: Phase I (phI) study evaluating the cardiac safety of oral chemotherapy s-1 in patients (pts) with advanced solid tumors.. , 2013, , .		1
57	Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME). <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592098054.	3.2	1
58	What is the best choice of partner chemotherapy with trastuzumab for metastatic breast cancer?. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 195-201.	2.4	0
59	Phase I en oncologie. Le dÃ©fi de dÃ©velopper de nouveaux agents thÃ©rapeutiques Ã l'Ã©chelle de la mÃ©decine personnalisÃ©e. <i>Medecine Nucleaire</i> , 2012, 36, 228-232.	0,2	0
60	Efficacy and Safety of Bevacizumab (Bv) and Irinotecan (I) in Elderly Patients with Recurrent Glioblastoma Multiform (Gbm): a Monocentric Retrospective Study. <i>Annals of Oncology</i> , 2014, 25, iv143.	1.2	0
61	PD5-3-2: Prognostic value of the number of examined lymph nodes in totally resected Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, S479.	1.1	0
62	Targeted deep sequencing from circulating plasma DNA as a multipurpose biomarker in pts (pts) referred for phase I trials.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11051-11051.	1.6	0
63	MEVITEM: A European, randomized, open-label Phase I/II of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent/ refractory medulloblastoma presenting an activation of the Sonic Hedgehog pathway.. <i>Journal of Clinical Oncology</i> . 2016. 34. TPS2083-TPS2083.	1.6	0
64	Outcome and follow-up of glioblastoma patients treated with bevacizumab based therapy in 2nd line treatment.. <i>Journal of Clinical Oncology</i> , 2016, 34, e13502-e13502.	1.6	0
65	Feasibility and benefit of molecularly-informed enrollment into early phase trials for patients with recurrent gliomas.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2004-2004.	1.6	0